Key result
Compound 1 and its analogue exhibited broad-spectrum antiviral activity against enteroviruses by directly inhibiting host factor PI4KIIIβ, and showed dose-dependent protection in a mouse pancreatitis model.
A novel inhibitor targeting host cell factor PI4KIIIβ demonstrates broad-spectrum antiviral activity against enteroviruses in vitro and protective efficacy in a preclinical mouse model.
Answers are grounded in this paper and cite their sources.
Supports PI4KIIIβ inhibition for enterovirus antivirals; leaves open translation from mouse models to patients.
Despite their high clinical and socioeconomic impacts, there is currently no approved antiviral therapy for the prophylaxis or treatment of enterovirus infections. Here we report on a novel inhibitor of enterovirus replication, compound 1, 2-fluoro-4-(2-methyl-8-(3-(methylsulfonyl)benzylamino)imidazo[1,2-a]pyrazin-3-yl)phenol. This compound exhibited a broad spectrum of antiviral activity, as it inhibited all tested species of enteroviruses and rhinoviruses, with 50% effective concentrations ranging between 4 and 71 nM. After a lengthy resistance selection process, coxsackievirus mutants resistant to compound 1 were isolated that carried substitutions in their 3A protein. Remarkably, the same substitutions were recently shown to provide resistance to inhibitors of phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ), a lipid kinase that is essential for enterovirus replication, suggesting that compound 1 may also target this host factor. Accordingly, compound 1 directly inhibited PI4KIIIβ in an in vitro kinase activity assay. Furthermore, the compound strongly reduced the PI 4-phosphate levels of the Golgi complex in cells. Rescue of coxsackievirus replication in the presence of compound 1 by a mutant PI4KIIIβ carrying a substitution in its ATP-binding pocket revealed that the compound directly binds the kinase at this site. Finally, we determined that an analogue of compound 1, 3-(3-fluoro-4-methoxyphenyl)-2-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine, is well tolerated in mice and has a dose-dependent protective activity in a coxsackievirus serotype B4-induced pancreatitis model.
No takes yet. Share an insight, caveat, or question.
Schaar et al. (2013) studied Enterovirus infections. Compound 1 and its analogue was evaluated on Antiviral activity and PI4KIIIβ inhibition. Compound 1 and its analogue exhibited broad-spectrum antiviral activity against enteroviruses by directly inhibiting host factor PI4KIIIβ, and showed dose-dependent protection in a mouse pancreatitis model.
Synapse has enriched 10 related papers. Consider them for comparative context: